高风险子宫内膜癌中复发性疾病的临床负担
Kalé Kponee-Shovein1, Vimalanand S Prabhu2, Yan Song3
1Analysis Group, Inc., 111 Huntington Avenue 14th Floor, Boston, MA, 02199, USA. Kale.Kponee-Shovein@analysisgroup.com.
Oncology and therapy
|July 12, 2025
概括
在接受化疗的高风险子宫内膜癌患者中,无病生存率 (DFS) 可以预测整体生存率 (OS). 复发性疾病显著增加了死亡风险,强调了对新疗法的需求.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 癌症研究 癌症研究
背景情况:
- 无病生存率 (DFS) 是子宫内膜癌试验中常见的终点.
- 在高风险病例中,其对整体存活 (OS) 的预测价值仍然不清楚.
- 这项研究调查了DFS作为高风险子宫内膜癌中OS的替代品.
研究的目的:
- 为了估计DFS和OS之间的相关性.
- 评估疾病复发和生存状况之间的关联.
- 评估DFS作为高风险子宫内膜癌中OS的潜在代用终点.
主要方法:
- 利用医疗保险数据 (2007-2019) 对接受辅助化疗的高风险子宫内膜癌患者.
- 使用卡普兰-梅尔分析估计的OS和DFS.
- 采用肯德尔的等级相关性和多变量考克斯模型来分析生存和复发的影响.
主要成果:
- 在DFS和OS之间发现了强烈的正相关性 (肯达尔的t = 0.83,p < 0.001).
- 经历复发的患者在基准点 (p < 0.001) 中死亡风险高3.8-5.2倍.
- 总体而言,复发导致死亡风险增加了7.9倍 (HR 7.9,p < 0.001).
结论:
- 在高风险的子宫内膜癌中,DFS显示出作为OS替代品的潜力.
- 疾病复发带来了相当大的死亡风险,突出了治疗缺口.
- 新的治疗策略对于减轻复发负担和改善治疗结果至关重要.
更多相关视频
05:16Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
Published on: August 4, 2021
3.5K
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
380
相关概念视频
Disorders of the Female Reproductive System
496
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
496
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
